News | September 17, 2014

After controversial withdrawal from Southampton General Hospital, Ashya King begins treatment in Prague

Pediatric Brain Tumor Patient From the U.K. Undergoes First Treatment of Proton Therapy

Ashya King's prescribed treatment plan for proton therapy


September 17, 2014 — Five-year-old Ashya King, the brain tumor patient whose case made headlines in Europe after his parents unlawfully took him from his hospital in Southampton, England, against the advice of doctors, began undergoing his prescribed treatment plan for proton therapy this week.

King was previously under the care of Southampton General Hospital for treatment of medulloblastoma. After unsatisfaction with the hospital’s treatment plan, King’s father sought more effective approaches through the Internet and came upon proton therapy. When the hospital refused to attempt it on King, his parents fled the United Kingdom to find a hospital that would, sparking a controversial debate.

The boy is now under the care of Motol University Hospital, where he is staying while undergoing treatment at the Proton Therapy Centre Czech in Prague. The overall course of treatment will take place over 30 visits; the first 13 will be to deliver irradiation to the entire tumor area—including the spinal cord, to ensure it is not spreading via cerebrospinal fluid—while the following 17 will be to treat just the tumor volume.

“There is a 70 to 80 percent survival rate for the condition such as the one Ashya has, and there is now every reason to hope that he will make a full recovery,” said his attending physician, Barbora Ondrová, M.D.

To illustrate the differences between proton therapy and conventional radiation therapy, the specialists at Proton Therapy Centre Czech drew up treatment plans for both techniques. In King’s case, it is necessary to apply the highest possible dose into the tumor but protect the tissue around it as much as possible. Vital structures to be protected include the heart, lung, liver and intestines. This means decreasing the risk of developing cardiovascular disorders, breathing disorders or metabolic disorders, and better protection of the swallowing functions and normal food intake.

For more information: www.ptc.cz


Related Content

News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | Radiation Therapy

June 19, 2024 — RaySearch Laboratories AB announced a milestone in radiotherapy technology where RaySearch’s RayStation ...

Time June 19, 2024
arrow
News | Radiation Oncology

June 3, 2024 — The American Society for Radiation Oncology (ASTRO) published an updated clinical guideline that details ...

Time June 03, 2024
arrow
Subscribe Now